open access

  • Abstract viewed - 469 times
  • PDF downloaded - 472 times
Submitted: 2021-05-11
DOI: 10.35119/myjo.v3i4.225
Case Reports
Published: 2021-12-03

Intravitreal moxifloxacin in acute post-phacoemulsification endophthalmitis: a case report

Dr. YAP Eye Hospital, Yogyakarta, Indonesia; Universitas Gadjah Mada Academic Hospital, Yogyakarta, Indonesia; Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Indonesian Ocular Infection and Immunology Society
Dr. YAP Eye Hospital, Yogyakarta, Indonesia; Universitas Gadjah Mada Academic Hospital, Yogyakarta, Indonesia; Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
Dr. YAP Eye Hospital, Yogyakarta, Indonesia; Department of Ophthalmology, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Indonesian Ocular Infection and Immunology Society
Indonesian Ocular Infection and Immunology Society; Nusantara Eye Clinic, Jakarta, Indonesia
Indonesian Ocular Infection and Immunology Society; Mitra Kelapa Gading Hospital, Jakarta, Indonesia
acute post-phacoemulsification endophthalmitis intravitreal moxifloxacin

Abstract

Background: Vancomycin and ceftazidime are commonly used intravitreal antibiotics to treat acute post-phacoemulsification endophthalmitis. However, they are not commercially available in appropriate therapeutic dose for intravitreal injection. Moxifloxacin is a broad-spectrum antibiotic that is commercially available in appropriate therapeutic dose for intravitreal injection, thus providing a rationale for its use in acute post-phacoemulsification endophthalmitis.
Case presentation: A 46-year-old female presented with blurred vision, redness, and pain in the right eye 5 days after phacoemulsification. Visual acuity was hand movement and conjunctival and circumcorneal injection, corneal oedema, anterior chamber reaction, and vitreous opacities were observed. The patient was treated with intravitreal moxifloxacin 500 μg/0.1 ml, vitrectomy, and topical and oral antibiotics. Visual acuity improved to 6/15 and follow-up at 5 weeks did not reveal any signs of intraocular inflammation.
Conclusion: Intravitreal moxifloxacin is an alternative in the treatment of acute post-phacoemulsification endophthalmitis.